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Abstract. Space light-emitting diode (LED) technology has provided medicine with a new tool capable of delivering light deep 
into tissues of the body, at wavelengths which are biologically optimal for cancer treatment and wound healing. This LED 
technology has already flow n on Space Shuttle missions, and shows promise for wound healing applications of benefit to Space 
Station astronauts.
PHOTODYNAMIC THERAPY
Photodynamic therapy (PDT) is a cancer treatment modality that recently has been applied as adjuvant therapy for 
brain tumors. PDT consists o f  intravenously injecting a photosensitizer, which preferentially accumulates in tumor 
cells, into a patient and then activating the photosensitizer with a light source. This results in free radical generation 
followed by cell death. The development o f  more effective light sources for PDT o f  brain tumors has been 
facilitated by applications o f  space light-emitting diode array technology; thus permitting deeper tumor penetration 
o f light and use o f  better photosensitizers. Lutetium Texaphyrin (Lutex) is a new, second generation photosensitizer 
that can potentially improve PDT for brain tumors. Lutex has a major absorption peak at 730 nm, which gives it two 
distinct advantages. First, longer wavelengths o f  light penetrate brain tissue easily so that larger tumors could be 
treated, and second, the major absorption peak means that more o f  the drug is activated upon exposure to light. 
Tumoricidal effects o f  Lutex have been studied in vitro using canine glioma and human glioblastoma cell cultures. 
Using light emitting diodes (LED) with a peak emission o f  728 nm as a light source, a greater than 50 percent cell 
kill was measured in both cell lines by tumor DNA synthesis reduction. The effectiveness o f  Lutex against tumor 
cells in vitro thus established, we have taken the first step toward determining its effectiveness in vivo by 
performing experiments to deten-nine the largest dose o f  both Lutex and light that can be administered to dogs 
before toxicity is seen i.e. the maximum tolerated dose (MTD). Using this dose allows us to effect maximum tumor 
cell destruction during in vivo studies. Based upon the MTD o f  Lutex in dogs, human trials are now anticipated.
WOUND HEALING
Wounds heal less effectively in space than here on earth. Improved wound healing may have multiple applications 
which benefiting civilian medical care, military situations and long-term space flight. Laser light and hyperbaric 
oxygen have been widely acclaimed to speed wound healing in ischemic, hypoxic wounds. Lasers provide low 
energy stimulation o f  tissues which results in increased cellular activity during wound healing. Some o f  these 
activities include increased fibroblast proliferation, growth factor synthesis, collagen production and angiogenesis. 
Hyperbaric oxygen therapy has also been shown to beneficially affect these processes.
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Lasers, however, have som e inherent characteristics which make their use in a clinical setting problematic, including 
limitations in wavelength capabilities and beam width. The combined wavelengths o f  light optimal for wound healing 
cannot be efficiently produced, and the size o f  wounds which may be treated by lasers is limited. Light-emitting diodes 
(LEDs) offer an effective alternative to lasers (Table 1, Figure 1). These diodes can be made to produce multiple 
wavelengths, and can be arranged in large, flat arrays allowing treatment o f  large wounds.
Our experiments suggest potential for using LED light therapy at 680, 730, and 880 nm simultaneously, plus hyperbaric 
oxygen therapy, both alone and in combination, to accelerate the healing process in Space Station missions, where 
prolonged exposure to microgravity may otherwise retard healing.
T A B LE  1. Output Specifications for Wound Treatment LED Array. , , . ■
Min Typ M ax
Surface Energy (670nm)
Power Output (m W cnr) 25 29 34
Quantum (umol M25' 1800 2100 2400
Surface Energy (735nm)
Power Output (mW/cm2) 25 29 34
I aairj
FIG U R E 1. LED Array for Treating Wounds at 670 nm and 735 nm.
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PART I - PHOTODYNAMIC THERAPY
Introduction
Photosensitizers are light sensitive molecules that upon activation with light can cause photodynamic damage to cells 
in which they localize (Henderson, 1992). For photodynamic therapy o f  solid tumors, in particular brain tumors a 
photosensitizer should selectively localize in malignant cells versus normal brain and be activated by light that can 
penetrate deeply into solid tissue. In general, light penetration in the brain and other solid tissues increases for light with 
longer wavelengths (Eggert, 1993). Therefore, in order to effectively treat solid tumors one must have a photosensitizer 
that absorbs light preferentially at long wavelengths.
Traditionally two similar photosensitizers, namely Hematoporphyrin and its more purified form Photofrin® have been 
the most widely applied in the adjuvant treatment o f  brain tumors (Kostron, 1996; Muller, 1995; Origitano, 1994; 
Popovic, 1995). Both o f  these photosensitizers have major absorption peaks in the short wavelengths o f  light and a 
smaller peak in the near infrared spectrum at 630 nm. At that wavelength, light penetration is limited and deeper 
photosensitized tumor cells are not eliminated because o f  the lack o f  light activation (Kostron, 1996). Therefore, one 
way to improve the efficacy o f  PDT o f  solid tumors is to use photosensitizers that can absorb at longer wavelengths o f  
light.
Red laser light is frequently produced using an argon ion or KTP/YAG laser beam that is converted by a dye module, 
usually to 630 nm. For longer wavelengths o f  light improved technology is required. Laser conversion to near-infrared 
wavelengths is inherently costly and inefficient, but allows for light to be delivered by fiberoptics. For non-fiberoptic 
delivery o f  light, other light sources could be a useful alternative.
Light-emitting diodes (LED) are one such light source that may prove to be an effective alternative to lasers for PDT. 
LED's have been frequently used to emit low power, broad spectrum light o f  25-30 nm bandwidths for photosynthesis 
research in plants. LED lamps traditionally consist o f  an array o f  semiconducting LED chips. In recent years, 
improvements in semiconductor technology have substantially increased the light output o f  LED chips. A novel type 
o f  LED chip is based on the semiconductor Aluminum Gallium Arsenide (A lG aA s). These LED chips can be 
manufactured to emit light with a peak wavelength between 630 nm and 940 nm. This range o f  wavelengths overlaps 
with the absorption spectrum o f  photosensitizers used for PDT o f brain tumors.
Lutetium Texaphyrin (Lu-Tex) is a new photosensitizer that has strong light absorption from 730 to 770 nm with 
absorption peak at 732 nm (Young, 1996). In addition, Lu-Tex is water-soluble and has a high, long-lived quantum 
yield for triplet states that can produce cytotoxic singlet oxygen.
The aim o f  this study was to evaluate the potential effects o f  Lu-Tex in combination with light-emitting diode balloon 
applicator on normal brain tissue and to investigate cytotoxicity in gliom a cell lines.
Materials and Methods
In vitro and in vivo experiments were conducted to document tumor-cell kill and neurologic safety in the delicate 
brainstem region (the posterior fossa) using PDT with LED-light and Lu-tex.
Lu-Tex In Vitro Experiments
Red light for PDT in vitro was produced by a Q-beam photosynthesis lamp (Figure 2) ( Quantum Devices, Inc, 
Bameveld, WI, USA). The emitting surface measured 6x10 cm and contained 198 light emitting diodes. The LED 
chips are on the surface o f  a ceramic sink with a ventilator to prevent overheating. In order to deliver LED light in vivo , 
an LED probe was constructed (Figure 2). The LED probe consists o f  a 10 cm hollow steel tube that has at its tip the 
LED chips arranged in a cylinder. The core o f  the tube contains three channels. One channel contains insulated wires
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To cooling fluid loop and LED power from portable control console
Access port
. . , . F IG U R E  2 . The LED Balloon Applicator in a Ischematic Overview. , . ,
which provide electricity for the LED tip. A second channel contains sterile water which acts as a cooling fluid when 
circulated around the tip. The third channel provides access for the 0.1 percent intralipid fluid used to inflate the balloon 
at the tip o f  the probe. The pump for the cooling fluid and the power supply are in a portable base unit. Power output 
o f the LED tip is adjusted via a potentiometer on the base unit which controls current flow. The temperature o f  the tip 
was continuously monitored and was not allowed to exceed 35° C at any time during the experiment. The balloon o f  
the LED probe was inflated with a 0.1 percent intralipid solution. Balloon diameter ranged from 2 cm to 5 cm. The 
tip o f  the LED probe was placed in the center o f  the balloon. In this configuration, the balloon is known to scatter light 
uniformly, with light irradiation varying by no more than twenty percent o f  the average when measured at any point 
on the balloon’s surface. The total power output was 1.0 watt at the tip and was kept constant.
All glioma cell lines were grown in monolayer tissue culture in P I00 tissue culture dishes at 37 °C in a humidified 5 to 
10 % CO: atmosphere, as previously described. Cultures were harvested by gently dislodging the cells from their 
substratum with a Pasteur pipette for in vitro assay. Glioma cells were then plated in 1.6 cm w ells o f  a 24 plate. 
Following 24 hours o f  attachment Lu-Tex was added in increasing concentrations form 0.0 to 30 fiM. All experiments 
were done in triplets. Control cells received an equal volume but no Lu-Tex. The Lu-Tex concentration used did not 
cause any dark toxicity. After 3 hours incubation in the dark the cells were exposed to the light from the LED lamp.. 
The energy density was 1.8 J/cm: . Approximately 24 hours after completion o f  LED treatment cell viability was 
assessed by measuring uptake for 3H-thymidine in DNA. After extraction the radioactivity was counted.
Lu-Tex in Vivo Experiments
Adult mongrel dogs weighing approximately 20 kg were used for in vivo PDT. All animals were incubated and placed 
under general anesthesia. A wide posterior fossa craniectomy was performed. A Y-shaped dural incision was extended 
to expose the cerebellum, lower brainstem and upper cervical spinal cord (Schmidt, 1994; Schmidt, 1996; Whelan,
1993). The LED balloon applicator with a diameter o f  2 cm was placed into the posterior fossa on the brainstem.. All 
canines received Lu-Tex 3 to 5 hours prior to light exposure ( except light only controls) in increasing doses starting 
a 0.75 mg/kg according to the Fibonacci dose escalation scale (Collins, 1986; Goldsmith, 1975). The maximum  
tolerated dose (MTD) was defined as the dose given to the group o f  canines that preceded the group with 50% neuro 
toxicity . The LED was adjusted to deliver light spectrum with a peak wavelength o f  732 nm and bandwidth o f  25 nm. 
The structural details o f  the probe and spectral analysis were published prevously (Schmidt, 1996).
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FIG U R E 3. Lu-Tex Dose (uM) 24 hr. Incubation.
Results
Photodynamic therapy (PDT) results in vitro demonstrate that LED light produces a photodynamic effect using Lutex 
which results in brain tumor cell killing. PDT results in vivo further demonstrate that LED light at 100 J/cm2 is safe with 
a maximum tolerable dose (M TD) o f  Lutex o f  1.6 mg/kg for treatment in the delicate brainstem regions.
Photodynam ic Therapy for Glioma Cells in Vitro
The graph in Figure 3 shows that Lu-Tex sensitized glioma cells are significantly inhibited when exposed to LED light. 
Light only and Lu-Tex only controls demonstrated no significant growth inhibition on gliom a cells (Figure 3).
Photodynam ic Therapy in Canine M odel
Table 2 summarizes the results o f  the canine neurotoxicity study. Light doses for up to 150 J/cm; had no effect on 
normal brain tissue if  the canines did not receive any Lu-Tex. Several animals in the Lu-Tex escalation study 
experienced mild post operative ataxia that resolved within 48 hours. One animal died 48 hours after PDT with 1.0 
mg/kg and 100J/cm2 light. Autopsy revealed a large extradural blood clot compressing the brainstem that was most 
likely traumatic. Other animals at the same dose showed no permanent deficits. The Lu-Tex dose was then escalated 
progressively at a constant light dose o f  100 J/ cm2. At 2.0 mg/kg Lu-Tex, all animals expired immediately after PDT 
( < 24 h) secondary to respiratory difficulties. In addition, they showed severe signs o f  quadraparesis, ataxia and 
swallowing difficulties. The dose was then decreased to 1.6 mg/kg. All animals experienced mild transient ataxia 
except for one canine which expired 48 hours after surgery. Autopsy revealed a normal brain structure unlike the 
animals at 2.0 mg/kg. We subsequently repeated the same dose o f  Lu-Tex and Light. These additional four canines 
had no permanent deficits. Thus, the MTD according to our protocol is 1.6 m g/kg and 100 J/cm2 (Table 2).
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0.5 to 075 6 < 150 none normal
1.00 to 1.25 6 100 1 mortality Cerebellar hemorrage
1.6 6 100 1 mortality Normal brain
2.0 _ 3 100 3 mortalities Severe brainstem edema
Discussion
Lutetium texaphyrin (Lu-Tex) is a pure, hydrophilic photosensitizer that is synthesized by inserting a lutetium metal 
into the center o f  ring shaped, planar porphyrin molecule called texaphyrin. The mechanism by which porphyrins 
including texaphyrins preferentially accumulate in cancer cells is not fully elucidated. Tumor localizing properties o f  
texaphyrins are related to high metabolism in cancer cells similar to other porphyrins. Texaphyrins can be engineered 
with different central metals which influences the biochemical reaction they mediate while retaining their tumor 
localizing properties. Gadolinium texaphyrin has been evaluated as a MRI contrast agent, radiationsensitizer and 
chemosensitizer while Lutetium texaphyrin has been developed as a photosensitizer (Kostenich, 1997; Woodbum, 1998; 
W oodbum, 1996; Young, 1996; Young, 1994; Young, 1996). Lu-Tex exhibits strong light absorption in the far red 
spectrum (730 to 770 nm, peak 732 nm) where tissue light penetration is at least doubled compared to 630 nm (Eggert,
1994).
The therapeutic efficacy for PDT o f  brain tumors has been demonstrated in several clinical and experimental studies 
(Kaye, 1988; Kaye, 1987; Muller, 1987; Muller, 1990; Muller, 1995; Muller, 1996). Most series for human recurrent 
gliomas use Photofrin or HP and 630 nm laser light, which has demonstrated a tumor response to treatment. Despite 
that success, local recurrence remains the most common cause o f  treatment failure after PDT just like after conventional 
treatment (Kostron, 1996). Most investigators think that this is most likely secondary to infiltrative tumor cell in the 
brain adjacent to tumor (BAT) (Powers, 1991). Studies have shown that photosensitizer is taken up in the BAT and that 
increasing the light dose which increases tissue light fluence demonstrates a greater therapeutic success (Hill, 1990; 
Muller, 1995). Another way to increase the light dose for deeper tissues is to increase the wavelength o f  the incident 
light into the far red spectrum. Unfortunately, Photofrin and HP absorb light poorly beyond 630 nm. New  
photosensitizers like BPD and Lu-Tex absorb light at longer wavelength (Aveline, 1994; Young, 1996).
Normal brain tissue toxicity can occur in PDT o f brain tumors. Several studies indicate that at high photosensitizer dose 
Photofrin, hematoporphyrin, and even second generation photosensitizers like Benzoporphyrin derivative, can sensitize 
normal brain tissue to photodynamic effect (Muller, 1987; Schmidt, 1994; Schmidt, 1996; Whelan, 1993). This study 
indicates that Lu-Tex can cause normal brain tissue damage at high doses (>2.0 mg/kg). With careful drug and light 
dosimetry this effect can be limited. At the MTD o f 1.6 mg/kg the canine brainstem tolerated PDT effects. In previous 
studies using the same posterior fossa canine model we demonstrated that normal tissue toxicity is related to high 
photosensitizer doses rather than high light doses. t
In addition to limited normal tissue toxicity, Lu-Tex also demonstrated the ability to inhibit the growth o f  glioma cells 
in vitro similar to other porphyrin based photosensitizers. Lu-Tex has been shown to be localized to metastatic brain 
tumors in humans. Thus, Lu-tex with LED light have the potential to effectively treat brain tumors.
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CONCLUSION
Lu-Tex combined with an LED light source can potentially increase the therapeutic efficacy o f  PDT o f  brain tumors 
without increasing normal tissue toxicity. Longer wavelengths o f  light than previously practical were provided by LED 
technology. The development by NASA o f  new light sources and light delivery devices is o f  critical importance for 
improving photodynamic therapy.
PART II - WOUND HEALING
Improved wound healing may have multiple applications which may benefit civilian medical care, military situations 
and long-term space flight.
In space, wounds may heal differently than here on earth. Laser light has shown some benefit for wound healing but 
has limited surface area and wave length. Light-emitting diodes, developed by NASA, offer the potential for dramatic 
improvement in wound healing over lasers for future space flight, civilian and military applications.
Laser light and hyperbaric oxygen have been widely acclaimed to speed wound healing in ischemic, hypoxic wounds. 
There have been few comparative studies done to document value over other methods such as meticulous surgical 
debridement, antibiotics, limited amputation, contact casting, adjunctive pentoxifyline, topical oxygen, topical growth 
factors, and careful attention to host factors such as diabetes control, nutrition, etc.
Light Studies
A category o f  lasers termed “soft” or “cold” lasers, provide low energy stimulation o f  tissues which may result in 
increased cellular activity during wound healing (Miller, 1993). This principal o f  laser biostimulation was introduced 
by the Russian’s over twenty years ago and is applied primarily in dermatology for skin wound healing. It has also been 
suggested that biostimulation by light may be useful in other wound healing scenarios. Low-powered lasers were used 
to treat areas o f  skin and accelerate wound healing. Subsequently, cold lasers have been used to provide pain relief and 
perform non-surgical face lifts. In eastern europe, helium neon-lasers with low power densities, were reported to 
stimulate skin graft healing in rabbits, regenerate burned skin in rats, and accelerate mucous membrane repair in the 
tongue in mice.
The proposed mechanism o f  action o f  low-powered light irradiation was supposed to effect cellular metabolic processes 
and improve regeneration potential (Gamaleya, 1977). There have been many problems trying to determine what wave­
lengths o f  light are best. The use o f  lasers has been problematic because o f  limited wave-length and beam physics 
(narrow beam o f coherent light). Studies have included different kinds o f  lasers, wave-lengths, time-exposures, energy 
settings, laboratory animals and cell types (Meyers, 1990).
Wound healing has three phases. First a substrate is laid down, then cells proliferate, then there is remodeling o f  tissue. 
The data published so far suggests that laser biostimulation produces its primary effect during the cell proliferation 
phase. It is felt that mitochondria are receptive to monochromic light and that these laser experiments have increased 
respiratory metabolism o f  certain cells (Meyers, 1990). Such things as fibroblast proliferation, collagen synthesis, 
growth factor production, including keratinocyte growth factor (KGF), transforming growth factor (TGF) and platelet- 
derived growth factor (PDGF), as well as macrophage stimulation, and greater rate o f  extracellular matrix production 
have been reported.
Lasers produce unique light irradiation differing from other light sources, but are limited in wavelength capabilities and 
beam width for technical reasons. Previous experiments, however, using lasers have demonstrated unique properties 
in biological systems. Scientists experimenting with low intensity laser’s attempting to evaluate effects on tissues and 
cell cultures have published articles about stimulating cell activity. Wavelengths have typically varied from 630 - 730 
nm but have been as high as 780 nm. Four Joules/cm2 o f  total light dose, with powers in the milliwatt range have
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typically been provided. Fibroblast proliferation, attachment and synthesis o f  collagen and procollagen have all been 
produced.
It was reported in earlier literature that helium neon laser light at 633 nm was optimal for wound healing (Basford, 1986) 
using 1 mW exposures and greater to provide 4 Joules/cm2 energy density. Later studies looking at in vitro skin 
fibroblast stimulation demonstrated that consecutive exposures o f  660 nm and 780 nm laser light at 24 hour intervals 
increased collagen production fourfold compared with untreated cultures (Lubart, 1992, 1997; Yu, 1997). Beauvoit 
(1994, 1995) demonstrated that mitochondria provide 50% o f  the tissue absorption coefficient and 100% o f the light 
scattering at 780 nm due to cytochrome aa3, cytochrome oxidase and other mitochondrials chromophores. Fibroblasts 
irradiated at 660 nm with 2.16 J/cm2 increased fibroblast growth factor synthesis and fibroblast proliferation (Yu, 1997). 
Concurrent DNA synthesis measurements confirmed this (Mester, 1973; Abergel, 1984). Karu (1989) demonstrated 
increased DNA synthesis by irradiation at 680 nm, increased protein synthesis at 750 nm, and increased cell proliferation 
at 890 nm, which was 10 times more effective than other near-infrared wavelengths, requiring only 1 J/cm2.. Laser 
stimulation o f  collagen synthesis measured by incorporation o f  radioactive amino acids was demonstrated at 693 nm 
with similar results. More recently, the work o f  Dr. Norman Salansky 44 has indicated that growth factor production 
and collagen synthesis may be improved at wavelengths o f  660 - 680 nm and stimulation o f  new small blood vessel 
growth was produced at 880 nm wavelength. Such studies have been limited by the constraints o f  laser technology, but 
LED’s offer improved power and area o f  distribution at longer wavelengths.
The mechanism o f  action is not fully understood, but possible explanations include stimulation o f  ascorbic acid uptake . 
by cells, stimulation o f  photo receptors in the mitochrondia respiratory chain, changes in cellular ATP or cAM P levels 
and cell membrane stabilization.
Animal studies in rats, mice, guinea pigs, and swine have been performed. Human studies have also occurred involving 
greater amounts o f  epithelialization for wound closure (Mccaughan, 1985). A number o f  other human studies have 
demonstrated that low energy laser systems promote tissue healing (Lyons, 1987; Kana, 1981; Mester, 1982; Kovacs, 
1982; Abergel, 1987; Cummings, 1985; Hunter, 1984; Karu, 1989; Braverman, 1989; Kovacs, 1974; Haini, 1982; 
Mester, 1985; Kahn, 1984; Chlebarov, 1988; Sugue, 1990). Other studies have demonstrated difficulties with human 
healing using laser systems. Wavelength and waveform o f  the optical source, power, output and three dimensional 
energy density o f  the system as well as the duration o f  individual treatments and treatment schedules, all limited by laser 
technology, would be improved with LED technology (Hunter, 1984; Surinchak, 1983; Basford, 1986; Brunner, 1986; 
Lundeberg, 1991; Santoianni, 1984; Gogia, 1992; Kana, 1982; Van Breugel, 1992; Braverman, 1989; Mester, 1985; 
Kroetlinger, 1980; Longo, 1987). In a study o f  nine patients with 12 leg ulcers, the combination o f  two light sources 
o f  660 nm and 880 nm wavelengths, each having a power o f  6 mW and energy density o f  4 Joules/cm2 produced 
differences o f  16.3 mm2/week (p=0.34) between placebo (1.3±4.7 mm2/week) and light-treated (17.6±6.4 mm2/week) 
groups, during the first 4 weeks o f  low energy photon therapy, but the assistance o f  another treatment modality to 
maintain the original rate o f  healing is required. :
It is believed that our experimental design will address these issues. We plan to use LED’s emitting light at 680 nm, 730 
nm, and 880 nm to stimulate growth factor production, collagen synthesis and microvascular angiogenesis in healing 
wound tissue. Furthermore, LED-treatment will be combined with hyperbaric oxygen and growth factor therapy.
Hyperbaric Studies
Publication o f  meticulously detailed studies that examine the use o f  HBO for specific problems have been slow, even 
though HBO therapy has been in clinical use since 1943. Both the difficulty and cost o f  developing controlled, double­
blind, randomized trials have impeded the scientific standards o f  medicine today, despite a progression o f  studies o f  the 
diabetic foot. Davis et al believed that appropriate historic controls for demonstrating the efficacy o f  hyperbaric therapy 
could be represented by patients with chronic wounds that were unresponsive to standard techniques (Davis, 1988). 
No prospective controlled trial has been used for the surgical technique for management o f  the diabetic foot problem 
(Davis, 1988; Davis, 1991; Cianci, 1993). And as stated by Feldmeier et al no double-blind studies exist in the entire 
field o f  radiation therapy (Feldmeier, 1996). Such studies are impossible for ethical and technical reasons.
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The necessity and expense o f  performing double-blind hyperbaric studies has long been recognized. Two commonly 
used study endpoints in hyperbaric studies are the outcome based reduction o f  amputation rates, and “healing”, defined 
as the lack o f  need for amputation above the ankle. Existing studies do not include an absolute measure o f  healing such 
as measurement o f  granulation tissue.
The medical practice paradox that compensates for limb amputation rather than limb salvage is frequently described 
by Cianci (1988) and Cianci (1994). The management o f  chronic wounds, especially in an aging society, is a growing 
problem that calls for novel techniques based on the wound microenvironment. Two approaches that specifically 
address the identified pathophysiologic processes are hyperbaric oxygen therapy and growth factor research. Hyperbaric 
oxygen therapy, however, is the most specific treatment for the identified abnormality.
Davies (1987) described a retrospective review o f  the group’s experience. Their findings demonstrated a 70% success 
rate o f  healing and a 30% failure. Patients who did not require amputation above the ankle were classified as successful. 
Patients with large vessel disease were often categorized as failures due to their limitations o f  distal perfusion.
In addition, several other retrospective articles have been published (Hart, 1979; Pedesini, 1984; Perrins, 1986; Oriani, 
1992) but the data reported by Stone (1995) and Stone and Scott (1995) is the most provocative. Stone et al found that 
patients who were referred for hyperbaric therapy showed more wounds per patient, greater wound volumes, and had 
a greater percentage recommended for amputation. Even though the wounds were more serious, the limb-salvage rate 
was greater in the hyperbaric treated group (72% versus 53%; p<0.002).
The data collected by Stone and Scott measured wound volumes by categorizing patients into three groups: standard 
care, standard care with adjuvant hyperbaric therapy, and both combined with growth factors. Standard care (60%  
healing) versus standard care with hyperbaric therapy (63% healing) showed no significant difference in healing rates. 
However, the average wound volume in the hyperbaric-treated group (2,750 mm3; n=38) was twice the size o f  the 
standard care group (1,144 mm3; n=250). The greatest healing rate was demonstrated by the group that was treated with 
the combination o f  standard care, hyperbaric therapy, and growth factors (80%; 2,414 mm3; n=49). Like animal studies 
this data suggests a synergistic effect o f  combination therapy. Thus, we will combine LED near infrared light, 
hyperbaric oxygen, and growth factors in our human treatment protocol.
Methods
Fibroblast Studies:
DNA synthesis in cultured 3T3 fibroblasts was measured after incubation in the presence and absence o f  4 J/cm2 o f  LED 
light at 680 nm, 730 nm and 880 nm using tritiated (3H) thymidine incorporation. After 3-4 hours in 0.01 mCi/ml 
(methyl 3H) thymidine (6.7 uCi/mole), cells were washed and assay stopped with 10% trichloroacetic acid. Cells were 
dissolved with 0.2N sodium hydroxide, and tritium uptake counted in liquid scintillant using a scintillation counter.
Animal Studies:
• 44 male Sprague-Dawley rats were wounded with a 35 mm full-thickness skin excision.
• Rats were divided into four groups which were treated as follows:
Group 1-Controls, no treatment 
Group 2-Experimental light treatment (ELT) only 
Group 3-Hyperbaric oxygen treatment (HBOT) only 
Group 4-ELT and HBOT
• ELT consisted o f  seventeen daily exposures to 4 Joules/cm2 each o f  680 and 730 nm light.
• HBOT consisted o f  seventeen daily exposures to 2.4 atmospheres o f  pure oxygen for 90 minutes.
• Wounds size was monitored by photography and analyzed by SigmaScan Pro software.
• Wound area was expressed as a percentage o f  original size; groups compared to by Student’s T-test.
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Results
Our in vivo wound healing experiments demonstrated a therapeutic benefit o f  LED light plus hyperbaric oxygen therapy 
(HBOT), especially in speeding the early phase o f  wound closure. This is particuiarily significant, since the treatment 
improved upon healing in a model using wounds in healthy rats.
Animal Studies:
Preliminary data indicate that ELT decreases wound size 7, 12, and 17 days after wounding when used alone and 7 and
12 days after wounding when com bined with HBOT (Figure 4) (Table 3).
H G roup 1 
E G roup 2 
■ G roup 3 
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FIG U R E 4. Reduction in Wound Size in Experimental Controls and Treated Rats.
T A B LE  3. Reduction in Wound Size in Experimental Controls and Treated Rats.
W ound Area. 
Percent of 
Original Sizes
Group Day 1 Day 3 Day 7 Day 12 Day 17
Untreated control 100 73.5±7.9 41.4±8.4 20 .4±3 .8 12.4±2.9
ELT only 100 69.2±5.7 33.2±6.2 14.1±3.7 8 .1±2.0
HBOT only 100 70.1 ±4.5 3 1.4±3.5 14.8±1.6 7 .2±1.6
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FIGURE 5. Increased DNA Synthesis In Fibroblasts Treated With LED Light Compared With Normal Control 
Expressed as (3H) Thymidine Uptake In Counts Per Minute
Cultured fibroblast data supports the animal data by demonstrating doubled DNA synthesis when cells were treated with 
LED light (Figure 5). This is particularly important since fibroblasts are the major cell type needed to grow and divide 
in healing wounds.
Discussion
As previously noted, prior studies involving lasers have demonstrated that light does help wound healing, but current 
applications o f  light therapy are limited to the use o f  low power laser light. Due to the nature o f  light physics and 
engineering constraints o f  laser design, the range o f  wavelengths attainable is limited. Due to the coherent beam o f  light 
unique to lasers, their ability to easily treat large areas is also limited. NASA's developm ent o f  light emitting diodes 
(LED) offers an alternative source for light therapy that can be designed to produce many wavelengths and in an array 
o f varied shape— thus enabling it to direct light over a large or 3-D surface. In this case study, the LEDs were designed 
to emit light at wavelengths proven, in prior studies o f  laser light, to speed wound healing. The LED’s were 
manufactured in a square box array to provide uniform energy density to the subject rats.
Cutured fibroblast data demonstrated doubled DNA synthesis in the cell type most proliferative in healing wounds. This 
provides tremendous encouragement in support o f  animal studies leading to human trials. Data in rats agrees. The data 
from this initial group shows that there is a role for LED therapy. The rats receiving LED therapy showed a significant 
increased wound healing when compared to controls. Additionally, this rate o f  healing was comparable to the rate 
resulting from the established daily hyperbaric oxygen treatment (HBOT) o f  2.4 ATA for 90 minutes. The current 
standard o f  care for problem wounds allows for the adjunctive therapy o f  HBOT in cases such as diabetic ulcers, graft 
failures, radiation necrosis, and other ischemic wounds. However, the access o f  patients to a hyperbaric treatment center 
is not always available, and many factors can make it difficult for patients to undergo high pressure treatments. Our 
initial data is promising in that it offers the first evidence to a second adjunctive modality for problem wounds. While 
the combined treatment o f  both LED and HBOT did increase wound healing when compared to controls, it did not offer 
synergistic effects on healing in this initial group. Additional studies with larger groups o f  rats, as well as the addition 
o f 880 nm LED-light in combination with 680 nm and 730 nm LED’s are currently underway, and may offer insight 
into mechanisms for improving synergy. Future human trials o f  LED and HBOT efficacy are also planned.
We anticipate that our continued trials will consistently demonstrate the efficacy o f  LED therapy on wound healing. 
The ability to make LEDs o f  various wavelengths, their low power consumption, and ability to design the actual LED 
array in various shapes and sizes makes it ideal for an adjunctive therapy. It has unique application to military and space 
environments, where speed o f  healing, durability, ease o f  operation, and portability are essential factors. LED excels 
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